Categories AlphaGraphs, Earnings, Health Care

Key highlights from Abbott Laboratories (ABT) Q2 2023 earnings results

Abbott Laboratories (NYSE: ABT) reported second quarter 2023 earnings results today.

Net sales decreased 11.4% year-over-year to $10 billion. Organic sales growth, excluding COVID-19 tests, was 11.5%.

GAAP net income decreased 32% to $1.37 billion, or $0.78 per share, from last year. Adjusted EPS fell 24.5% to $1.08.

For full-year 2023, adjusted EPS is expected to range between $4.30-4.50.

Prior performance

Most Popular

Nike (NKE) looks set to beat hurdles and build a brighter future

Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business

Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company

Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as

Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor

Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications

Add Comment
Viewing Highlight